Dihydroartemisinin-Piperaquine vs. Artemether-Lumefantrine for First-Line Treatment of Uncomplicated Malaria in African Children: A Cost-Effectiveness Analysis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DHA/PPQ with its longer prophylactic tail has been modelled to be more cost-effective and superior in reducing clinical incidence and malaria prevalence than AL as first-line treatment in higher transmission settings; however, its impact in lower transmission settings like Ethiopia is less clear [45, 46].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bhattarai, A., Ali, A. S., Kachur, S. P., Mårtensson, A., Abbas, A. K., Khatib, R., Al-mafazy, A.-W., Ramsan, M., Rotllant, G., Gerstenmaier, J. F., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040309 · Cited by 647 · cited 1×
“The choice of first-line antimalarial drug for treatment of uncomplicated Plasmodium falciparum malaria is critical in preventing the progression of acute infections to severe disease and reducing the risk of further morbidity, disability and premature mortality from the disease [2].”
Background
Research works printed but not linked: 24
- A Roca-Feltrer, 2008, Estimates of the burden of malaria morbidity in Africa in children under the age of 5 years, Trop Med Int Health, 13, 771, 10.1111/j.1365-3156.2008.02076.x · DOI
- M Malmberg, 2013, Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania, Malaria Journal, 12, 103, 10.1186/1475-2875-12-103 · DOI
- Q Bassat, 2009, Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial, PLoS ONE, 4, e7871, 10.1371/journal.pone.0007871 · DOI · Paper page
- 2011, A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial, PLoS Med, 8, e1001119, 10.1371/journal.pmed.1001119 · DOI
- M Nambozi, 2011, Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children, Malar J, 10, 50, 10.1186/1475-2875-10-50 · DOI
- GR Awab, 2010, Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial, Malar J, 9, 105, 10.1186/1475-2875-9-105 · DOI
- A Shaukat, 2012, Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment, Malaria Journal, 11, 207, 10.1186/1475-2875-11-207 · doi:10.1186/1475-2875-11-207
- AR Hasugian, 2007, Dihydroartemisinin-Piperaquine versus Artesunate-Amodiaquine: Superior Efficacy and Posttreatment Prophylaxis against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax Malaria, Clinical Infectious Diseases, 44, 1067, 10.1086/512677 · DOI · Paper page
- S Moon, 2009, Focusing on Quality Patient Care in the New Global Subsidy for Malaria Medicines, PLoS Med, 6, e1000106, 10.1371/journal.pmed.1000106 · DOI
- A Briggs, 1998, An introduction to Markov modelling for economic evaluation, Pharmacoeconomics, 13, 397, 10.2165/00019053-199813040-00003 · DOI · Paper page
- White L (2012) Malaria in the Asia-Pacific: Modelling the current and potential impact of artemisinin resistance and its containment. Malaria Conference 2012.
- Y Lubell, 2011, Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa, Bull World Health Organ, 89, 504, 10.2471/BLT.11.085878 · DOI
- AM Dondorp, 2010, Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial, Lancet, 376, 1647, 10.1016/S0140-6736(10)61924-1 · DOI · Paper page
- Lopez AD, Guillot M, Inoue M, Ferguson BD, Salomon JA (2001) Life tables for 191 countries for 2000: Data, methods, results (GPE discussion paper no. 40) Health Systmens performance assessment peer review Technical documentation IV Outcomes: Population Health World Health Organization (WHO).
- Murray C and Lopez, A.: The Global Burden of Disease: A comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and projected to 2020. Harvard School of Public Health; 1st edition (ISBN-13: 978-0674354487).19. World Bank (1993) World Development Report: Investing in Health. Washington, DC.
- P Ayieko, 2009, The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malaria and meningitis, Cost Eff Resour Alloc, 7, 3, 10.1186/1478-7547-7-3 · DOI
- S Shillcutt, 2008, Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy, Bull World Health Organ, 86, 101, 10.2471/BLT.07.042259 · DOI · Paper page
- E Arinaitwe, 2009, Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children, Clin Infect Dis, 49, 1629, 10.1086/647946 · DOI
- JA Mulligan, 2006, The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania, Trop Med Int Health, 11, 452, 10.1111/j.1365-3156.2006.01590.x · DOI
- WA Davis, 2011, Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea, Bull World Health Organ, 89, 211, 10.2471/BLT.10.084103 · DOI
- K Stepniewska, 2008, Pharmacokinetic determinants of the window of selection for antimalarial drug resistance, Antimicrob Agents Chemother, 52, 1589, 10.1128/AAC.00903-07 · DOI
- DJ Creek, 2013, Pharmacokinetic Predictors for Recurrent Malaria After Dihydroartemisinin-Piperaquine Treatment of Uncomplicated Malaria in Ugandan Infants, Journal of Infectious Diseases, 207, 1646, 10.1093/infdis/jit078 · doi:10.1093/infdis/jit078
- N White, 2008, How antimalarial drug resistance affects post-treatment prophylaxis, Malaria Journal, 7, 9, 10.1186/1475-2875-7-9 · DOI · Paper page
- D Ubben, 2013, MMV in partnership: the Eurartesim® experience, Malaria Journal, 12, 211, 10.1186/1475-2875-12-211 · DOI
Cited by
Assefa, A., Mohammed, H., Anand, A., Abera, A., Sime, H., Minta, A. A., Tadesse, M., Tadesse, Y., Girma, S., Bekele, W., et al. (2022) · Malaria Journal · doi:10.1186/s12936-022-04350-z · Cited by 20
Metadata
- Authors
- Pfeil, J., Borrmann, S., & Tozan, Y.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-04-18
- Volume
- 9
- Issue
- 4
- Pages
- e95681
- ISSN
- 1932-6203
- Cited by
- 17
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.